Trevi Therapeutics, Inc. Derivative Liability, Fair Value, Gross Liability
Trevi Therapeutics, Inc. (TRVI) had Derivative Liability, Fair Value, Gross Liability of $202.00 thousand as of 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Notes
us-gaap:DerivativeFairValueOfDerivativeLiability · last filed 2022-03-17
- 2021-03-31: Derivative Liability, Fair Value, Gross Liability $202.00K.
- 2020-12-31: Derivative Liability, Fair Value, Gross Liability $196.00K.
- 2020-09-30: Derivative Liability, Fair Value, Gross Liability $187.00K.
| Period end | Derivative Liability, Fair Value, Gross Liability |
|---|---|
| 2021-03-31 | $202.00K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $196.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $187.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |